Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Teladoc Health in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Teladoc Health’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:54 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001477449-26-000038
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Cost of revenue (exclusive of depreciation and amortization, which are shown separately below) | 190,837 | 190,537 | 388,363 | 387,366 |
| Advertising and marketing | 143,397 | 167,547 | 294,924 | 335,732 |
| Sales | 49,391 | 49,951 | 100,667 | 98,644 |
| Technology and development | 62,861 | 68,784 | 130,726 | 138,742 |
| General and administrative | 104,029 | 108,114 | 206,122 | 220,888 |
| Goodwill impairment | — | — | — | 59,138 |
| Acquisition, integration, and transformation costs | 1,690 | 2,658 | 2,754 | 4,846 |
| Restructuring costs | 904 | 5,692 | 12,879 | 10,039 |
ITEM 1. Financial Statements
FAQ
- What is Teladoc Health's R&D?
- Teladoc Health (TDOC) reported R&D of $62.86M in Q2 2026.
- How has Teladoc Health's R&D changed year-over-year?
- Teladoc Health's R&D decreased by 8.6% year-over-year, from $68.78M to $62.86M.
- What is the long-term trend for Teladoc Health's R&D?
- Over 4 years (2021 to 2025), Teladoc Health's R&D has grown at a -2.8% compound annual growth rate (CAGR), from $311.88M to $277.92M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Teladoc Health's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude